APA (7th ed.) Citation

KITAGAWA, C., KADA, A., SAKA, H., SAITO, A. M., & ICHINOSE, Y. (2018). Rationale and Design of a Randomized Phase 2 Trial of Gefitinib Plus Bevacizumab vs Gefitinib Alone in Patients with Epidermal Growth Factor Receptor Mutant Non-Squamous Non-Small-Cell Lung Cancer: Study Protocol. Kurume medical journal, 65(2), 77-81. https://doi.org/10.2739/kurumemedj.MS652001

Chicago Style (17th ed.) Citation

KITAGAWA, CHIYOE, AKIKO KADA, HIDEO SAKA, AKIKO M. SAITO, and YUKITO ICHINOSE. "Rationale and Design of a Randomized Phase 2 Trial of Gefitinib Plus Bevacizumab Vs Gefitinib Alone in Patients with Epidermal Growth Factor Receptor Mutant Non-Squamous Non-Small-Cell Lung Cancer: Study Protocol." Kurume Medical Journal 65, no. 2 (2018): 77-81. https://doi.org/10.2739/kurumemedj.MS652001.

MLA (9th ed.) Citation

KITAGAWA, CHIYOE, et al. "Rationale and Design of a Randomized Phase 2 Trial of Gefitinib Plus Bevacizumab Vs Gefitinib Alone in Patients with Epidermal Growth Factor Receptor Mutant Non-Squamous Non-Small-Cell Lung Cancer: Study Protocol." Kurume Medical Journal, vol. 65, no. 2, 2018, pp. 77-81, https://doi.org/10.2739/kurumemedj.MS652001.